KALA BIO, Inc. (KALA) Q1 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Kala Bio, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.049 -- 00:00:04.233 Good morning and welcome to the Cali Pharmaceuticals conference call to review its first 00:00:04.233 -- 00:00:07.316 quarter 2022 financial results. 00:00:07.316 -- 00:00:10.239 At this time, all participants are in listen-only mode. 00:00:10.239 -- 00:00:13.422 Following management's prepared remarks, a Q&A session will be held. 00:00:13.422 -- 00:00:16.125 As a reminder, this call is being recorded. 00:00:16.125 -- 00:00:20.970 I would now like to turn the call over to Jill Steyer, Executive Director, Investor Relations 00:00:20.970 -- 00:00:23.292 and Corporate Communications for Cali Pharmaceuticals. 00:00:23.292 -- 00:00:25.553 Please proceed. 00:00:25.885 -- 00:00:29.807 Thank you, Operator, and thank you all for participating in today's call. 00:00:29.807 -- 00:00:35.049 Joining me from the company are Mark Iwiki, Chief Executive Officer, Todd Basemore, 00:00:35.049 -- 00:00:40.091 President and Chief Operating Officer, Kim Brazel, Head of R&D and Chief 00:00:40.091 -- 00:00:45.494 Medical Officer, Mary Remus, Chief Financial Officer, and Darius 00:00:45.494 -- 00:00:50.436 Karabi, our Chief Business Officer, will also be joining us for the Q&A portion of today's 00:00:50.436 -- 00:00:56.352 call. During this call, we will make certain comments about CALA's future expectations, 00:00:56.352 -- 00:01:00.655 plans, and prospects that are forward-looking statements within the meaning of the Private 00:01:00.655 -- 00:01:04.698 Securities Litigation Reform Act of 1995. 00:01:04.698 -- 00:01:10.022 These statements will include observations associated with our commercialization of ISUVIS 00:01:10.022 -- 00:01:14.806 and INVELTUS, statements regarding the development, program, and market potential of 00:01:14.806 -- 00:01:16.816 ...